
ACADIA Pharma (ACAD) Stock Forecast & Price Target
ACADIA Pharma (ACAD) Analyst Ratings
Bulls say
Acadia Pharmaceuticals Inc. has reported a strong quarter characterized by heightened healthcare provider (HCP) and patient engagement, which supports increased awareness and demand for its products, particularly NUPLAZID, prompting management to enhance its customer-facing team by 30% in 1Q26. The company has narrowed its revenue guidance for NUPLAZID to a range of $1.07 - $1.095 billion, reflecting a favorable reception from a direct-to-consumer (DTC) campaign, while also anticipating significant growth opportunities in the adult patient segment as it represents 60% of the current market share. Additionally, initial positive impacts from the sales force expansion are expected to yield meaningful benefits into 2026, reinforcing confidence in the company's financial performance moving forward.
Bears say
ACADIA Pharmaceuticals Inc. faces significant commercial risks that contribute to a negative outlook on its stock, primarily linked to potential stagnation in the growth of its core product, NUPLAZID, which may not meet revenue expectations in future clinical studies or regulatory approvals. There are concerns regarding the stalled launch of DAYBUE for Rett syndrome and the possibility of disappointing outcomes for other pipeline drugs, which could hinder the company’s ability to penetrate the market successfully. Financial performance may also be challenged, as evidenced by 3Q25 revenues of $101.1 million falling slightly below consensus expectations, highlighting the risks associated with its key products and the reliance on successful commercialization strategies.
This aggregate rating is based on analysts' research of ACADIA Pharma and is not a guaranteed prediction by Public.com or investment advice.
ACADIA Pharma (ACAD) Analyst Forecast & Price Prediction
Start investing in ACADIA Pharma (ACAD)
Order type
Buy in
Order amount
Est. shares
0 shares